Account
Insider Insights
05.09.2024
NICE’s 1000th Appraisal: Iptacopan for Paroxysma...

The recent appraisal by the National Institute for Health and Care Excellence (NICE) for Iptacopan, ...

Read more
Insider Insights
28.08.2024
NICE rejects first drug proven to slow Alzheimerâ€...

Despite positive outcomes in treating Alzheimer's disease, NICE cites small benefits and high costs ...

Read more
Insider Insights
16.08.2024
Health Technology Evaluation

Key findings from the ABPI's latest report highlight challenges and opportunities in NICE's health t...

Read more
Insider Insights
15.08.2024
Significant update in US drug pricing: Medicare to...

The Biden administration’s recent drug price negotiations under the Inflation Reduction Act re...

Read more
Insider Insights
14.08.2024
Spanish Ministry of Health unveils long-awaited Dr...

The Spanish Ministry of Health's Draft Royal Decree on HTA reshapes assessments, aligning with EU-H...

Read more
Insider Insights
08.08.2024
World’s first CRISPR-based Gene Therapy Exa-cel ...

NICE recommends gene therapy for severe beta-thalassaemia, offering hope for improved quality of lif...

Read more
Insider Insights
23.07.2024
Saudi Arabia’s rise: from emerging market to...

The Saudi Food & Drug Authority (SFDA) released guidelines for Economic Evaluation Studies to assess...

Read more
Insider Insights
11.07.2024
AIFA publishes report on pharmaceutical national a...

Increase in net spending and challenges in balancing healthcare budgets highlighted in AIFA's latest...

Read more
Insider Insights
09.07.2024
HAS relaxes evidence requirements under certain co...

New doctrine accelerates drug development for rare diseases and oncology by adjusting evidence requi...

Read more
Insider Insights
08.07.2024
New German Medicines Research Act: confidential re...

Germany's new Medicines Research Act allows confidential rebates for pharma companies, but recent am...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.